EGFR and non-small cell lung carcinoma: In another real‐world study analyzing the clinical outcomes of NSCLC patients with brain metastasis, the T790M‐positive rate did not differ significantly between patients using an EGFR‐TKI plus bevacizumab and those using EGFR‐TKI monotherapy (66.7% vs. 75.0%, p = 0.460).37